Results 51 to 60 of about 10,281 (182)

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Nicotine addiction and the influence of life adversity and acute stress on PYY: Prediction of early smoking relapse

Pharmacology Research & Perspectives
Early life adversity (ELA) is associated with earlier initiation and maintenance of tobacco smoking and with a greater risk of subsequent relapse. There is growing evidence that appetite hormones, including peptide YY (PYY), which modulates craving and ...
Amanda A. Miller, Motohiro Nakajima, Briana N. DeAngelis, Dorothy K. Hatsukami, Mustafa al'Absi   +4 more
doaj   +1 more source

The last‐step integrator thesis: Heterarchical control of the mammalian gastrointestinal tract

The Journal of Physiology, EarlyView.
Abstract figure legend Heterarchy of control of the gastrointestinal tract. The production mechanisms (i.e. epithelial cells and muscles) are shown at the bottom in green. Above them are some of the many mechanisms that provide control inputs to these production mechanisms.
William Bechtel, Leonardo Bich
wiley   +1 more source

A Cross-Sectional Comparative Study: Could Asprosin and Peptide Tyrosine-Tyrosine Be Used in Schizophrenia to Define the Disease and Determine Its Phases?

Diagnostics
Background/Objectives: We aimed to evaluate asprosin and peptide tyrosine–tyrosine (PYY) levels in schizophrenia patients and the relationships between these levels and clinical severity, as well as whether these two hormones have a role in determining ...
Elif Özcan Tozoğlu, Nilifer Gürbüzer, Alev Lazoğlu Özkaya, Sümeyya Akyıldırım   +3 more
doaj   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Peptide YY and Glucagon-like Peptide-1 Secretion in Obesity

Gastrointestinal Disorders
Objective: The regulation of food intake is disturbed in obesity, possibly resulting from alterations in gut peptide secretion. We hypothesize that obesity is associated with attenuated systemic and tissue concentrations of the gut peptides PYY and GLP-1.
Jennifer Wilbrink, Mark van Avesaat, Arnold Stronkhorst, Freddy Troost, Carel W le Roux, Ad Masclee   +5 more
doaj   +1 more source

Effects of Weight Loss Interventions on Gut Microbiota‐Derived Metabolites Linked to Cardiometabolic Health: A Systematic Review and Meta‐Analysis

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT Background Gut microbiota‐derived metabolites are emerging as potential mediators between obesity and cardiometabolic conditions. While weight loss interventions modify microbiota composition, their effects on systemic microbial metabolites remain unclear.
Fernando Q. Iorra, Leonardo André Swarowsky Loebens, Andrea Auler, Eduarda Caroline Tasso Nascimento, Beatriz D. Schaan, Patrícia Martins Bock   +5 more
wiley   +1 more source

Secretion of Gut Hormones and Expression of Sweet Taste Receptors and Glucose Transporters in a Rat Model of Obesity

Obesity Facts, 2019
Objectives: This study was undertaken to compare gut hormone secretion between high-fat-fed and control rats, and to examine the corresponding changes in the expression of sweet taste receptors and glucose transporters in the small intestine and ...
Ri Lu Feng, Cheng Qian, Lian Yong Liu, Qian Jing Liu, Yun Qiu Jin, Sheng Xian Li, Wei Liu, Chris K. Rayner, Jing Ma   +8 more
doaj   +1 more source

Short‐Chain Fatty Acids: Microbial Metabolites Driving Gut‐Eye Axis Signaling

Comprehensive Physiology, Volume 16, Issue 5, October 2026.
Short‐chain fatty acids generated by gut microbial fermentation link diet to ocular physiology via the gut–eye axis. Through systemic distribution, these metabolites regulate GPCR signaling, epigenetic pathways, inflammation, and angiogenesis, shaping retinal homeostasis and highlighting therapeutic potential in ocular vascular and inflammatory ...
Aleah J. Brokemond, Ronny Amamoo, Fapianey J. Alexandre, Sewedo B. Ajisegiri, Menaka C. Thounaojam, Pamela M. Martin, Ravirajsinh N. Jadeja   +6 more
wiley   +1 more source